CTLA-4 inhibitors are typically administered via intravenous infusion. The dosing schedule can vary depending on the specific drug and the type of cancer being treated. For example, ipilimumab is often given every three weeks for a total of four doses when treating melanoma. The treatment regimen may be adjusted based on the patient's response and the occurrence of side effects.
